<DOC>
	<DOCNO>NCT02504463</DOCNO>
	<brief_summary>This study determine pharmacokinetics ( PK ) [ 14c ] -samidorphan healthy male volunteer .</brief_summary>
	<brief_title>A Study 14c-Samidorphan ( Also Known ALKS 33 ) Healthy , Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Body mass index ( BMI ) great than/equal 19 less than/equal 32 kg/m^2 screening ( minimum weight 50.0 kg ) Generally good health Subjects must agree reduce risk female partner become pregnant study 30 day last dose study drug abstinence heterosexual relationship use reliable contraceptive method Additional criterion may apply Clinically significant illness within 30 day History alcohol opioid dependence , positive urine toxicological screen marijuana , cocaine , amphetamine , opioids , barbiturate , benzodiazepine History oral gastrointestinal disease Irregular bowel bladder function History allergy hypersensitivity opioid medication opioid antagonist ( eg , naltrexone , naloxone ) Current pending legal charge probation would interfere study conduct Use alcohol within 24 hour prior admission urine positive test alcohol screen admission Tobacco nicotine use within 90 day Anticipated need prescription medicine study period Additional criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>ALKS 33</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>